We studied the in vivo interaction of ceftazidime and tobramycin in normal volunteers and anuric patients given each drug separately or both drugs in combination. Kinetic analysis of plasma concentration data showed minor changes in the disposition of these agents when they were given concurrently. However, the resulting clearance of both tobramycin and ceftazidime was unchanged when these drugs were given concurrently. The volume of distribution of tobramycin at steady state was increased by 20% in normal volunteers when given with ceftazidime. The increase in distribution was accompanied by a slight decrease in ceftazidime elimination rate. No additional alteration in dosing over those necessary to adjust for a decrease in renal function is necessary when giving this combination.
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The combination of aminoglycoside and P-lactam antibiotics is commonly used to treat serious infections caused by gram-negative bacilli. Many of these combinations exhibit synergistic activity against clinically important pathogens, and their concurrent use may delay the emergence of resistant bacterial strains (1, 7, 8, 17, 19) .
The chemical inactivation of both classes of antibiotics has been shown when they are mixed in vitro (10) . Although the precise mechanism of this interaction is not known, chemical inactivation is thought to occur through the opening of the P-lactam ring by an amino group of the aminoglycoside (15) .
In addition, the elimination kinetics of aminoglycosides are altered by the concurrent administration of P-lactam drugs in patients with normal or impaired renal function (3, 5, 6, (9) (10) (11) 16 ). This interaction is clinically important because the more rapid elimination of the aminoglycoside may result in subtherapeutic drug concentrations. The chemical inactivation of the aminoglycoside observed in vitro has been assumed to be the cause of the increased rate of aminoglycoside elimination observed in vivo. Chemical inactivation of the ,Blactams is less important because of the greater molar excess of the ,B-lactams.
Ceftazidime is a new broad-spectrum 3-lactamase-resistant cephalosporin. We tested the hypothesis that the concurrent administration of ceftazidime will influence the rate of tobramycin elimination in vivo. In addition, we determined the effects of concurrent tobramycin administration on the pharmacokinetics of ceftazidime.
MATERIALS AND METHODS Volunteers. Twelve adult male subjects were studied. Six were volunteers with normal renal function, and six were anuric patients undergoing hemodialysis. Persons were excluded from the study if (4) . Solutions of known concentrations of ceftazidime were prepared by diluting ceftazidime of certified potency in antibiotic-free pooled human plasma to final concentrations of 20, 10, 5, 2.5, 1.25, and 0.625 mg/liter. Samples were diluted with pooled human plasma until the concentration was within the range of the standard curve. Plasma containing tobramycin was completely inactivated enzymatically by mixing acetyl transferase and acetyl coenzyme A with each sample and incubating the mixture at 37°C for 20 min. Serum spiked with tobramycin and enzymatically inactivated did not show any antimicrobial activity. Furthermore, exposure of ceftazidime to the inactivation process did not alter its antimicrobial activity. The lower limit of the assay was 0.625 mg/liter, and the assay had a coefficient of variation of 6%. Urine containing ceftazidime was assayed by using a high-performance liquid chromatography method with UV detection at 254 nm. Urine was diluted, filtered with a Millipore membrane filter (pore size, 0.22 ,im), and injected directly on a 10-,um C18 Waters Associates RCM column. The mobile phase consisted of 7.0% acetonitrile in 0.2 M ammonium acetate flowing at 1.5 ml/min. Standards consisted of 500 and 250 ,ug of ceftazidime per ml in pooled blank urine. Retention time was approximately 6.5 min. The lower limit of the assay was 0.1 mg/liter, and the assay had a coefficient of variation of 4%. All assays were performed in triplicate. High-performance liquid chromatography analysis of serum was not performed because of interfering peaks in the uremic serum.
Concentrations of tobramycin in plasma and urine were determined by a fluorescence polarization immunoassay (Abbott TDX; Abbott Diagnostics Div., Irving, Tex.). The range of quantitation of the assay was between 0.18 and 12.0 mg/liter. The coefficient of variation was 10%o. Plasma and urine spiked with ceftazidime did not interfere with the assay of tobramycin. All assays were performed in triplicate.
Kinetic analysis. Pharmacokinetic analysis was performed by model-independent methods. The elimination rate constant , was determined by a log-linear regression of the five terminal concentration-time points. The total body clearance (CLT) was determined by CLT = dose/AUC, where AUC is the area under the plasma concentration-time curve (determined by the trapezoidal rule with a tail correction). The area-derived volume of distribution (Varea) was calculated by Varea = dose/ -AUC. The volume of distribution at steady state (Vrs) was calculated by Vs, = dose * AUMC/AUC2, where AUMC is the area under the first moment curve calculated using the trapezoidal rule by substituting t * C for C alone.
Statistics. Results were reported as the mean and the standard deviation of the mean. A Wilcoxon signed-ranks test was performed on the volume of distribution data because of unequal variances. A paired t test was performed on all other measured data. A result of P < 0.05 was considered significant.
RESULTS
Normal volunteers were 32 + 5 years of age, weighed 78 ± 16 kg, and had a creatinine clearance of 111 ± 16 ml/min. Anuric patients were 48 + 10 years of age, weighed 77 ± 17 kg, and did not make urine.
Concentrations of tobramycin in the plasma of normal volunteers and anuric patients are shown in Fig. 1 and 2 , respectively. The pharmacokinetic parameters derived from these data are shown in Table 1 . Coadministration of ceftazidime with tobramycin resulted only in a significant decrease The concentrations of ceftazidime in the plasma of normal volunteers and anuric patients are shown in Fig. 3 and 4 , respectively. The pharmacokinetic parameters derived from these data are shown in Table 2 . Coadministration of tobramycin with ceftazidime did not alter the pharmacokinetics of ceftazidime in either normal volunteers or anuric patients.
Uremia resulted in a significant decrease in the elimination rate constant and total body clearance of ceftazidime. Also, uremia resulted in a significant decrease in the Vss. The calculated volume of distribution (area) was greater in the anuric group but did not achieve statistical significance.
No changes in parameters reflecting measurements of renal or hepatic function were shown during the study. Both drugs were well tolerated by all recipients. been well documented in vitro. The magnitude of the interaction has been shown to vary with the agents involved and to depend on the duration of the admixture, the temperature of incubation, the composition of the medium, and the relative molar concentrations of the agents tested (13) (14) (15) 18) . These agents have also been shown to interact in vivo. The elimination rate of the aminoglycosides has been increased following the coadministration of penicillins. However, the effect of penicillin administration on aminoglycoside elimination is most pronounced in patients with impaired renal function (3, 6, 16 ).
In the current study, coadministration of ceftazidime However, the increase in Vss was offset by the slight decrease in the tobramycin elimination rate constant. These changes in V., and elimination rate constant resuited in no change in the total tobramycin clearance. Therefore, these changes are of little clinical significance. Also, there were no changes in the pharmacokinetic parameters of the anuric patients. The changes observed in the normal volunteers for the tobramycin pharmacokinetic parameters were mirrored in the measurements for ceftazidime. There was no change in ceftazidime clearance. However, the elimination rate constant decreased, and the V,, increased. Also, ceftazidime pharmacokinetic parameters in the anuric patients were unchanged. None of these differences achieved statistical significance. The kinetics of tobramycin are similar to those we have previously reported (2) . However, the kinetics of ceftazidime are different from those in previously reported studies. Specifically, the volume of distribution in the present study is over twofold greater than previously reported (12) . Some error may be introduced by the extrapolation of the area under the curve to infinity. The extrapolated area constituted 49% of the AUC in anuric patients and 11% of the AUC in normal volunteers. Since the AUC is used to calculate the volume of distribution, confidence in the calculated volumes is not great. However, it is still valid to make comparisons between groups in the current study.
The observed pharmacokinetic interaction between the aminoglycoside tobramycin and the cephalosporin ceftazidime was the opposite of that observed for aminoglycosides and penicillins and was almost nonexistent. Previous studies showed an increase in the elimination of the aminoglycoside, primarily in renal failure patients (3, 6, 16 ). In the current study, the tobramycin elimination rate constant was decreased in the normal volunteers. We conclude that tobramycin and ceftazidime may compete for similar renal elimination pathways, since the observed changes occurred only in the normal volunteers. Chemical inactivation of the aminoglycosides appears to occur in penicillin derivatives containing the five-membered thiazolidine ring. Species containing the cephem nucleus or compounds similar to it such as moxalactam (2) are not chemically inactivated but still may exhibit a pharmacokinetic interaction. The magnitude and direction of the changes in the pharmacokinetic parameters are of little clinical significance, and additional dosage adjustments over those to adjust for a decrease in renal function are not necessary when giving this combination.
